Literature DB >> 15582114

Disruption of learned irrelevance in acute schizophrenia in a novel continuous within-subject paradigm suitable for fMRI.

Andrew M J Young1, Veena Kumari, Ravi Mehrotra, David R Hemsley, Chris Andrew, Tonmoy Sharma, Stephen C R Williams, Jeffrey A Gray.   

Abstract

Learned irrelevance (LIrr) is closely related to latent inhibition (LI). In LI a to-be-conditioned stimulus (CS) is prexposed alone prior to the opportunity to learn an association between the CS and an unconditioned stimulus (UCS). In LIrr preexposure consists of intermixed presentations of both CS and UCS in a random relationship to each other. In both paradigms preexposure leads in normal subjects to reduced or retarded learning of the CS-UCS association. Acute schizophrenics fail to show LI. LI is usually demonstrated as a one-off, between-groups difference in trials to learning, so posing problems for neuroimaging. We have developed a novel, continuous, within-subject paradigm in which normal subjects show robust and repeated LIrr. We show that this paradigm is suitable for functional magnetic resonance imaging (fMRI) and gives rise, in normal subjects, to activation in the hippocampal formation, consistent with data from animal experiments on LI. We also report, consistent with previous studies of LI, loss (indeed, significant reversal) of LIrr in acute (first 2 weeks of current psychotic episode) schizophrenics. Chronic schizophrenics failed to demonstrate learning, precluding measurement in this group of LIrr. These findings establish the likely value of the new paradigm for neuroimaging studies of attentional dysfunction in acute schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15582114     DOI: 10.1016/j.bbr.2004.05.034

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  8 in total

1.  Examining associations between psychosis risk, social anhedonia, and performance of striatum-related behavioral tasks.

Authors:  Nicole R Karcher; Elizabeth A Martin; John G Kerns
Journal:  J Abnorm Psychol       Date:  2015-08

2.  Transient inactivation of the neonatal ventral hippocampus impairs attentional set-shifting behavior: reversal with an α7 nicotinic agonist.

Authors:  Julie M Brooks; Michelle L Pershing; Morten S Thomsen; Jens D Mikkelsen; Martin Sarter; John P Bruno
Journal:  Neuropsychopharmacology       Date:  2012-07-11       Impact factor: 7.853

3.  Learned irrelevance and associative learning is attenuated in individuals at risk for psychosis but not in asymptomatic first-degree relatives of schizophrenia patients: translational state markers of psychosis?

Authors:  Ariane T Orosz; Joram Feldon; Andor E Simon; Leonie M Hilti; Kerstin Gruber; Benjamin K Yee; Katja Cattapan-Ludewig
Journal:  Schizophr Bull       Date:  2010-01-15       Impact factor: 9.306

4.  The social-emotional processing stream: five core constructs and their translational potential for schizophrenia and beyond.

Authors:  Kevin N Ochsner
Journal:  Biol Psychiatry       Date:  2008-07-01       Impact factor: 13.382

Review 5.  Behavioral and neural mechanisms of latent inhibition.

Authors:  Dylan B Miller; Madeleine M Rassaby; Katherine A Collins; Mohammad R Milad
Journal:  Learn Mem       Date:  2022-01-18       Impact factor: 2.460

6.  Human electrophysiological correlates of learned irrelevance: effects of the muscarinic M1 antagonist biperiden.

Authors:  Inge Klinkenberg; Arjan Blokland; Wim Riedel; Anke Sambeth
Journal:  Int J Neuropsychopharmacol       Date:  2011-11-18       Impact factor: 5.176

7.  Dissociable effects of 5-HT2C receptor antagonism and genetic inactivation on perseverance and learned non-reward in an egocentric spatial reversal task.

Authors:  Simon R O Nilsson; Elizabeth M Somerville; Peter G Clifton
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

8.  Assessing the construct validity of aberrant salience.

Authors:  Kristin Schmidt; Jonathan P Roiser
Journal:  Front Behav Neurosci       Date:  2009-12-23       Impact factor: 3.558

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.